骨巨细胞瘤mdm2、p185、p21及p53免疫组化研究

目的]探讨mdm2、p185、p21及p53在骨巨细胞瘤（GCT）的表达及与GCT病理分级和复发的关系。方法]应用SP免疫组织化学方法检测mdm2、p185、p21及p53在52例GCT中的表达（GCT按Jaffe分级：Ⅰ级15例、Ⅱ级25例、Ⅲ级12例）。结果]52例GCT中mdm2、p185、p21及p53的阳性表达率分别为34.6%（18/52），21.2%(11/52),13.5%(7/52)及26.f9%(14/52)。不同病理分级阳性表达均无显著性差异。mdm2、p185、p21、p53在复发和无复发的病例中，阳性表达率分别为61.5%(8/13)、25.6%(10/39);38.5(5/13)、15.4%（6/39）；23.1%(3/13)、10.3%(4/29);46.2%(6/13)、20.5%(8/39)。GCT复发与否之间的mdm2表达有显著性差异（P=0.018)，而p185、p21及p53的表达无显著性差异。结论]mdm2、p185、p21及p53在GCT中的表达与病理分级差异无关，而mdm2的表达与其复发与否有关。

Immunohistochemical Analysis of mdm2,p185,p21 and p53 Protein Expression in Giant Cell Tumors of Bone

To investigate the relationship of mdm2,p185,p21 and p53 protein overexpression with pathological types and recurrence of human giant cell tumor of bone.Antibodies directed against mdm2,p185,p21 and p53 protein were used to measure expression of these protein in the cells from sections of the giant cell tumors of bone.The expressions of mdm2,p185,p21 and p53 in 52 surgically removed specimens from patients with giant cell tumor of bone were 34.6% (18/52),21.2%(11/52),13.5%(7/52),26.9%(14/52)respectively.The expressions of mdm2,p185,p21 and p53 in patients with recurrence and no recurrence,were 61.5%(8/13),25.6%(10/39);38.5%(5/13),15.4%(6/39);23.1%(3/13),10.3%(4/29) and 46.2%(6/13),20.5%(8/39)respectively.There was a striking statistically significant correlation between the expression of mdm2 protein and recurrence (P=0.018).However,there was no association between mdm2,p185,p21 and p53 positive cases and recurrence.Conclusion]There is a statistically significant correlation between the expression of mdm2 protein in the giant cell tumor of bone and recurrence.However,there is no statistically relationship between the expression of mdm2,p185,p21 and p53 protein in the giant cell tumor of bone and pathological types.